EGFR Molecular Classification In Vivo

Status Completed

Clinical Trial Summary

The investigators developed 18F-IRS as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-activating mutational status.

Clinical Trial Description

The goal of investigators were to evaluate the use of 18F-IRS as a novel PET/CT radiotracer to monitor EGFR-activating mutational status and identify EGFR-TKIs benefit NSCLC patients. the investigators want to evaluated the use of 18F-IRS in lung cancer imaging in adult NSCLC patients with different EGFR mutational status of primary and metastatic cancers. ;

Study Design

Related Conditions & MeSH terms

Molecular Imaging

Clinical Trial Details

NCT number	NCT03031522
Study type	Interventional
Source	Harbin Medical University
Contact
Status	Completed
Phase	N/A
Start date	September 1, 2014
Completion date	December 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02916329` - In Vivo EGFR-ECD Molecular Imaging Using [68Ga]- Labelling Anti-EGFR Affibody Molecule	N/A
Completed	`NCT01944215` - Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue	Phase 1
Recruiting	`NCT02916394` - In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule	N/A
Active, not recruiting	`NCT03358589` - Molecular Evaluation in Metastatic Breast Cancer	N/A
Recruiting	`NCT02717221` - In Vivo EGFR Molecular Classification and Treatment Response	N/A
Completed	`NCT03233243` - Rosuvastatin Effect on Atherosclerotic Plaque Metabolism	Phase 4
Completed	`NCT02323217` - I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers	Early Phase 1
Enrolling by invitation	`NCT05575765` - Clinical Validation of Multimodal Digestive Endoscopy